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Abstract
 
Activation-induced deaminase (AID) is a protein indispensable for the diversification of immu-
noglobulin (Ig) genes by somatic hypermutation (SHM), class switch recombination (CSR),
and gene conversion. To date, the precise role of AID in these processes has not been deter-
mined. Here we demonstrate that purified, tetrameric AID can deaminate cytidine residues in
 
DNA, but not in RNA. Furthermore, we show that AID will bind and deaminate only single-
stranded DNA, which implies a direct, functional link between hypermutation and transcription.
Finally, AID does not target mutational hotspots, thus mutational targeting to specific residues
must be attributed to different factors.
Key words: B lymphocytes • immunoglobulin gene • activation-induced deaminase • 
somatic hypermutation
 
Introduction
 
Secondary antibody diversification is achieved by somatic
hypermutation (SHM), gene conversion, and class switch
recombination (CSR)
 
*
 
 of the Ig genes during the adaptive
immune response. In B cells, SHM and gene conversion
effectively mutate the Ig variable (V) regions, thereby
changing the affinity of antibody for antigen. CSR replaces
the Ig
 
 
 
 heavy chain constant region with a downstream
constant region, thereby altering the physical properties of
the resulting antibodies. All three events depend on activa-
tion-induced cytidine deaminase (AID), but the exact role
of this protein has remained elusive.
It has been proposed that AID directly deaminates DNA,
as ectopic overexpression of this protein has been shown to
result in dramatically increased levels of mutation in non-
germinal center B cells (1), non-B cells (2), and even 
 
Escher-
ichia coli
 
 (3). However, mutation could arise through multi-
ple mechanisms, and the available data could fit any of the
following theoretical possibilities. First, as initially con-
ceived, AID could be an RNA editing enzyme whose
overexpression would lead to promiscuous RNA editing,
as is the case for overexpressed APOBEC-1 (4). Second,
AID could be deaminating cytidine, dCTP or CTP,
thereby potentially altering the composition of the cellular
nucleotide pools, and it is well understood that even subtle
pool alterations can lead to mutagenesis in bacteria (5). Fi-
nally, DNA itself could be the substrate for AID. Indeed,
parallel work has persuasively pointed to uracil DNA gly-
cosylase (ung) as a factor in the somatic hypermutation
pathway (6, 7): ung would remove the uridine product of
cytidine deamination from DNA. Here, we demonstrate
that purified AID is a DNA deaminase and that its preferred,
in vitro substrate is ssDNA.
 
Materials and Methods
 
Purification of strepAID.
 
Starting with human AID cDNA, we
cloned strepAID into the pet3d vector (Novagen) and used the
construct to transform Rosetta (Novagen). Protein expression
was induced by treating bacterial cultures at OD 0.8 with 2 mM
IPTG for 3 h.
To purify strepAID, bacteria were lysed with B-PER (Pierce
Chemical Co.). Lysates were precleared on Q-sepharose FF (Am-
ersham Biosciences) and then loaded onto freshly prepared phos-
phocellulose (P-11; Whatman). StrepAID was eluted from P-11
with 0.4 M KCl. The eluate was diluted and loaded onto monoQ
(Amersham Biosciences). Purified strepAID tetramer was gradi-
ent-eluted from monoQ at 500 mM salt. A detailed protocol can
be furnished upon request.
 
DT40 aid
 
 
 
/
 
 
 
 Complementation Assays.
 
We cloned human
AID cDNA, strepAID, or GST-AID into the pMSCV-gfp retrovi-
ral vector (CLONTECH Laboratories, Inc.). Pantropic virus pro-
duced in 293GP cells (CLONTECH Laboratories, Inc.) was used
 
to infect DT40 aid
 
 
 
/
 
 
 
 cells (8). Gfp
 
 
 
 cells were sorted four days af-
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Abbreviations used in this paper:
 
 AID, activation-induced cytidine
deaminase; CSR, class switch recombination; EMSA, electromobility
shift assay; SNuPE, single nucleotide primer extension assay.T
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ter infection, and plated in bulk. To assess gene conversion, cells
were stained with anti-chicken IgM-PE (clone M1; Southern Bio-
technology Associates, Inc.) and visualized on a FACSVantage™.
 
Electromobility Shift Assay and UV-Cross-Linking.
 
Oligonucle-
otide substrate (100 ng) was T4 polynucleotide kinase labeled
with 0.1 mCi 
 
 
 
-P
 
32
 
ATP. 1 ng substrate was combined with 100–
200 ng strepAID in 10 
 
 
 
l binding reactions (containing 10 mM
Hepes pH7.6, 10% glycerol, 100 mM KCl, 10 mM MgCl
 
2
 
, 0.1
mM EDTA, and 0.5 mM DTT) at room temperature for 40 min.
For electromobility shift assay (EMSA) analysis, the entire reac-
tion was loaded on 4–20% acrylamide gels (BMA or Bio-Rad
Laboratories) and electrophoresed in tris-glycine running buffer at
100 V on a Bio-Rad Laboratories Mini-Protean apparatus until
the bromophenol blue dye front had reached the bottom of the gel.
For UV cross-linking, reactions (in 0.5 ml microfuge tubes)
were placed on ice, 1.5 cm from the light source and exposed for
10 min at 254 nm in a Stratagene UV Stratalinker. These samples
were heated to 95
 
 
 
C for 5 min in 1% SDS before loading on the
same 4–20% acrylamide gels electrophoresed at 200 V with 0.1%
SDS in the running buffer.
Gels were dried and images were stored on phosphor screens
and analyzed on STORM or Typhoon Phosphorimagers with
ImageQuant software.
 
Deamination Assays.
 
The standard buffer used in the deami-
nation assay (Figs. 3 b, 4, and online supplemental Fig. S2 b) con-
tained 100 mM KCl, 6 mM Hepes, 5 mM EDTA, at pH 7.6. at a
temperature of 30
 
 
 
C. However, AID was able to deaminate
DNA in a range of conditions including 50–150 mM salt, 7.6–9.0
pH, and 23–37
 
 
 
C.
10 ng of gel-purified oligonucleotide substrates (for sequences
see below) were incubated with 100–200 ng AID for 30 min. A
tenth of each reaction (1 ng) was used for primer extension with
Bst polymerase (a thermophilic Klenow fragment (New England
Biolabs, Inc.; Figs. 3 b, 4, and online supplemental Fig. S2 b) or
Taq (unpublished data). Briefly, a 25 
 
 
 
l reaction containing 1 ng
template, 1 ng primer, and Bst buffer was incubated at 70
 
 
 
C be-
fore the addition of 0.5 units Bst. The reaction temperature was
first lowered to the appropriate primer annealing temperature for
10 s, and then raised to 65
 
 
 
C (the optimal temperature for Bst).
After 1 min extension at 65
 
 
 
C the reaction was terminated by the
addition of sample loading buffer, heated to 95
 
 
 
C, and loaded on
a 14% denaturing gel (Sequagel; National Diagnostics). It is im-
portant to note that these reaction conditions were calibrated spe-
cifically for the template-primer pairs reported here and should be
faithfully followed: longer annealing or extension times, or higher
amounts of polymerase will increase background signal.
After drying, gels were exposed to phosphor storage screens
(Amersham Biosciences) and those were scanned on a Typhoon
imager using ImageQuant software (Molecular Dynamics).
 
SNuPE
 
 
 
Oligonucleotide Substrates.
 
RNA oligos were custom
synthesized by Dharmacon, Inc., and DNA oligos were made by
FisherOligos. 
 
Templates.
 
ACCint: agtaaatgaaACCgaatgtatgagaatagaagagata-
atga.
ACCend: aACCgaatgtatgagaatagaagagataatgaataatagaa.
TCGint: agtaaatgaaTCGgaatgtatgagaatagaagagataatga.
TCGend: aTCGgaatgtatgagaatagaagagataatgaataatagaa.
 
Primers.
 
PrExACC: atctcttctattctcatacattcG (annealing T 
 
 
 
58
 
 
 
C).
PrExTCG: atctcttctattctcatacattcC (annealing T 
 
  
 
57
 
 
 
C).
 
Oligonucleotide Substrates for EMSA and uv-Cross-Linking.
 
ssRNA:
aUCGgaauguaugagaauagaagagauaaugaauaauagaa.
ssDNA: aTCGgaatgtatgagaatagaagagataatgaataatagaa.
 
dsDNA (hp): multiple sequences, including: (a) aTCGgaatg-
tatgagaatagaagagataatgaataatagaattctattattcattatctcttctattctcatacattc
CGAt; (b) alternating dCdG 66mer.
 
TLC Oligonucleotide Substrates.
 
End labeled RNA: Cgaaugu-
augagaauagaagagauaaugaauaauagaa.
Body-labeled RNA was created by transcribing pBlue-
script II SK- (linearized with XhoI) with T7 RNA poly-
merase.
 
Online Supplemental Material.
 
We use TLC, EMSA, and SN-
uPE to demonstrate (a) that AID does not deaminate RNA and
(b) that APOBEC1 binds and deaminates ssDNA in vitro. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20030481/DC1.
 
Results and Discussion
 
We sought to determine which of a number of possible
substrates (RNA, CTP, dCTP, cytidine, or DNA) was
deaminated by purified AID protein in vitro. Before over-
expressing tagged protein in bacteria for purification pur-
poses, we wanted to know that the tag did not interfere
with the function of the protein in vivo. Thus we at-
tempted to complement DT40 aid
 
 
 
/
 
 
 
 cells (8) with (a)
empty virus, (b) minimally tagged AID (N-terminal strep-
Tag, henceforth strepAID), and (c) GST-AID. DT40 aid
 
 
 
/
 
 
 
cells infected with untagged AID and strepAID were able to
recover gene conversion within 4 wk after infection (Fig. 1
a,
 
 
 
and unpublished data), whereas GST-AID was unable to
complement AID deficiency (Fig. 1 a). We conclude that
GST-AID is inactive in vivo, possibly because the bulky tag
interferes with the proper folding of the protein.
We decided to overexpress minimally tagged, strepAID
protein in bacteria and attempted to purify it to homogene-
ity. Even though the protein was soluble, we noticed that
at most 5% of the tagged protein would bind Strep-Tactin
resin, possibly because the tag was buried in the protein.
We then decided to purify strepAID through standard bio-
chemical methods. One of the preferred resins for binding
DNA deaminases is phosphocellulose (9). We found that
strepAID did bind P-11 resin and eluted from it with a
peak around 0.4M KCl. We have thus purified strepAID
and putative active site mutants of AID such as a E58Q/
C87A/C90A mutant (henceforth referred to as mutant
strepAID) to relative purity (Fig. 1 b).
To verify the identity of the phosphocellulose-bound
product, putative strepAID protein was boiled in SDS
loading buffer, run on a denaturing gel, and Western blot-
ted. Recombinant protein reacted both with anti-AID an-
tibody and with streptavidin (10; Fig. 1 b and unpublished
data). We also noticed that phosphocellulose-bound re-
combinant protein would invariably run with the predicted
size of an AID tetramer. The tetramer could be broken up
only when the protein was boiled in strong denaturants
(such as urea, guanidine) and EDTA (Fig. 1 c). These ex-
periments suggest that in solution, strepAID is a tetramer.
Indeed, many deaminases are multimers (mostly dimers or
tetramers), and many retain that configuration even on de-
naturing acrylamide gels (examples include APOBEC-1, it-
self a dimer and BSD, a tetramer; references 11 and 12).T
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We tested the cytidine deaminase activity of the purified
strepAID tetramer in a standard TLC assay. Incubation of
CTP (or dCTP) with strepAID tetramer for 1hr did not re-
sult in deamination to UTP (or dUTP). In contrast, cdd, a
 
Bacillus subtilis 
 
cytidine deaminase (9), converted over 90%
of CTP (or dCTP) to UTP (or dUTP) within minutes
(online supplemental Fig. S1, lane 2 vs. lane 4, and unpub-
lished data). We also tested the ability of the purified
strepAID tetramer to deaminate cytidine, in a spectropho-
tometric conversion assay (13). Incubation of cytidine with
strepAID tetramer for 1 h did not result in conversion to
uridine although cdd converted 50 to 75% of cytidine to
uridine within minutes (unpublished data). We conclude
that neither cytidine nor CTP (or dCTP) are good sub-
strates for AID activity in vitro.
If DNA or RNA were good substrates, AID binding
to oligonucleotides would be expected. To determine
whether strepAID would bind nucleic acids under physi-
ologic conditions we performed standard EMSA. Indeed,
strepAID bound single stranded RNA and DNA, but not
dsDNA (Fig. 2 a). Binding was robust, as it could withstand
a 25-fold excess of either double stranded DNA competitor
(polydIdC; Fig. 2 b, lane 6), or tRNA competitor (Fig. 2 b,
lane 4) and was observed with or without cytidine in the
substrate (unpublished data). Mutant strepAID did not bind
to ssDNA at all (Fig. 2 b, lanes 5, 7, and 9), though it did
retain some binding to RNA (Fig. 2 b, lane 2).
When the binding reaction was UV-irradiated and ana-
lyzed by SDS-PAGE, the P
 
32
 
-labeled protein-DNA complex
migrated at the same position as the strepAID tetramer (rela-
tive to the protein standards). StrepAID cross-linked to ssDNA
but did not cross-link to double stranded DNA, or to RNA-
DNA substrates (online supplemental Fig. S2 and unpub-
lished data); neither mutant strepAID nor inactive, GST-AID
showed any cross-linking to ssDNA but did cross-link to
RNA (Fig. 2, c and d). Mutants of better-studied deaminases,
such as APOBEC-1, lose substrate binding as well as activity
when the cysteine residues of the active site are lost (14).
Hence, it is possible that the preferred substrate for AID in
vitro is DNA, but that AID, which is highly basic, nonspecif-
ically interacts with RNA, perhaps on the basis of charge.
To directly assess whether AID would deaminate RNA,
we compared its activity to that of recombinant GST-
APOBEC-1 (henceforth APOBEC-1) in a TLC assay (15).
Incubation of APOBEC-1 with an artificial RNA oligo-
mer containing a single cytidine at the 5
 
 
 
end, led to the
deamination of the cytidine to uridine (online supplemen-
tal Fig. S1, lane 7). In contrast, incubation with AID did
not lead to cytidine deamination (online supplemental Fig.
S1, lane 8). It is possible that AID is structurally limited to
catalysis on internal cytidines, so we also incubated these
proteins with internally labeled RNA substrates. Again,
though APOBEC-1 was able to catalyze deamination, AID
was not (online supplemental Fig. S1, lanes 10 and 11).
While we cannot exclude the possibility that AID acts on a
specific RNA (of unknown sequence), our data thus far
suggests that RNA is not a good substrate for AID in vitro.
To ascertain that strepAID would not only bind but also
deaminate DNA we developed a single nucleotide primer
extension assay (SNuPE). In this assay, a primer that ends just
short of the potential deoxyuridine is annealed to the DNA.
A polymerase (Taq or Bst, a thermophilic Klenow fragment)
Figure 1. Minimally tagged, strepAID is
active in vivo and assembles into a tetramer
in vitro. (a) DT40aid /  cells can recover
gene conversion activity after infection with
strepAID virus, but not after infection with
GST-AID virus (assay as per reference 8).
(b) Phosphocellulose-purified recombinant
strepAID runs with the predicted size of a
tetramer. Left: Western with anti-AID anti-
body (reference 10). Right: silver stained
gel. (c) Western blot which shows that AID
tetramer (gray arrow) can be dissociated
into trimer and monomer (black arrows)
upon boiling in buffer containing denatur-
ants and EDTA (lanes 2–4) but not in stan-
dard sample buffer (lane 1) or in EDTA
alone (20 mM EDTA and 3%  -mercapto-
ethanol, lane 5). The molecular weight assign-
ments for trimers and monomers is based on
their relative position on the denaturing gel
compared with protein standards. Lanes 2–4
show samples boiled in: 50% formamide
and 50 mM EDTA (lane 2), 0.8 M urea and
50 mM EDTA (lane 3), 25 mM Tris (pH
8), 10 mM EDTA, and 2% SLS (lane 4).T
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is then added to the reaction, along with a single radioactive
nucleotide. Under stringent annealing conditions, the poly-
merase will extend the primer by one (radioactive) nucle-
otide only if the nucleotide precisely complements the tem-
plate (16; Fig. 3 a). The primer extension reaction can then
be run on a sequencing gel and visualized by autoradiogra-
phy. In control reactions, we found that Taq or Bst would
add P
 
32
 
-dATP to a primer only if the template had a de-
oxyuridine at the appropriate position, but not if the tem-
plate had a different nucleotide (e.g., deoxycytidine, de-
oxyguanine or deoxyadenosine; Fig. 3 b). We did not detect
the incorrect addition of any of the other three P
 
32
 
-dNTPs
to the primer under these reaction conditions (Fig. 3 b).
To determine the sensitivity of this assay, we diluted
template containing a deoxyuridine at a known position
with the identical template but containing deoxycytidine in
that position. We found that the assay would consistently
detect the uridine-containing template when it comprised
as little as 1% of the template pool (Fig. 3 c, lane 10).
Hence, using single nucleotide primer extension we can
specifically detect uridine in DNA.
To measure the conversion of deoxycytidine to deoxy-
uridine in DNA, and hence, the DNA deaminating capac-
ity of strepAID, we created an artificial oligonucleotide
substrate containing a single deoxycytidine close to the
5
 
 
 
end. We then treated this substrate with strepAID and
assayed the conversion of the lone deoxycytidine to de-
oxyuridine by SNuPE. We could indeed detect deoxyuri-
dine in DNA after strepAID treatment (Fig. 3 c, lanes 5
and 6 shown in duplicate). The level of deamination, in
comparison to standards containing uridine, ranged from
1% to a maximum of 10% of the input molecules (Fig. 3 c,
lanes 5 and 6, and unpublished data). This reaction was
rapid (occurred within 10 min though it peaked at around
30 min, unpublished data), and did not occur when the
substrate was incubated with BSA, mutant strepAID, or
cdd (Fig. 3 c, lanes 1–4, and unpublished data). In addi-
tion, strepAID did not deaminate double stranded DNA
(Fig. 3 c, lanes 7 and 8). Deamination by strepAID was
observed within a range of deamination conditions: (a) salt
levels were important (they were kept within a 50–150
mM range), (b) the reaction could tolerate moderate levels
of EDTA (5–10 mM [17]), (c) it would work at a wide
range of pH (from 7.6 to 9.0 were tested), (d) and it would
work with varying efficiencies from room temperature to
37
 
 
 
C. In addition, like other deaminases (11) the protein
was still active after being heated at 65
 
 
 
C for 30 min be-
fore the addition of substrate. Our data suggests that, un-
der a range of conditions, strepAID is able to rapidly
deaminate single stranded DNA in vitro.
Figure 2. Recombinant strepAID preferentially
binds ssDNA. (a) EMSA: strepAID can bind single
stranded DNA and RNA but does not bind double
stranded DNA. (b) EMSA: an active site mutant of
AID (E58Q/C87A/C90A) retains some ability to bind
RNA (compare lanes 1 and 2) but cannot bind single
stranded DNA (lanes 5, 7, and 9). Binding of strepAID
is resistant to a 25-fold excess of tRNA (lane 4) or
polydIdC (lane 6). (c) AID can be uv-cross-linked to
RNA and ssDNA, and the cross-linked species run
with the predicted size of an AID tetramer (closed tri-
angle). Mutant AID can be uv-cross-linked to RNA,
and the bacterial cytidine deaminase cdd can be cross-
linked weakly to DNA (open triangle). (d) GST-AID
can be uv-cross-linked to RNA but not to ssDNA or
dsDNA (closed triangle).T
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We also tested whether APOBEC-1, could deaminate
DNA. APOBEC-1, a known RNA deaminase, has been
shown to confer a mutator phenotype on 
 
E. coli 
 
(3
 
)
 
. RNA,
ssDNA, and dsDNA oligonucleotide substrates of random
sequence could all be cross-linked to APOBEC-1 (online
supplemental Fig. S2 a, gray arrow, pairs denote duplicate
experiments). In contrast to strepAID, APOBEC-1 deami-
nated RNA of random sequence (online supplemental
Fig. S1, lanes 7 and 10). Furthermore, like strepAID,
APOBEC-1 deaminated ssDNA, but not dsDNA (online
supplemental Fig. S2 b, duplicate lanes 2 and 3 vs. 7 and 8).
Thus, the mutator phenotype conferred on both bacterial
and mammalian cells by APOBEC-1 overexpression (3, 4)
is most likely due to the ability of this enzyme to target
ssDNA under conditions where the enzyme is uncoupled
from the confines of the larger RNA editing complex
within which it normally functions. It thus seems that
APOBEC-1 may have dual specificities whereas AID ap-
pears to be active only on ssDNA.
Point mutations are not introduced randomly in the vari-
able regions of Ig genes. Rather, mutations preferentially
accumulate over “hotspot” motifs, and investigators have
mined the database of known mutations to create tables as-
signing mutability probabilities to nucleotide triplets (18).
Overexpression of AID appears to be sufficient for hypermu-
tation, so we asked whether AID itself could impart hotspot
preference to the hypermutation machinery. To approach
this question, we created DNA substrates that contained
deoxycytidine in the context of known mutational hotspots
(GCT, AGC, and its reverse complement TCG) and in the
context of coldspots (ACC, TCT) (18). StrepAID deami-
nated deoxycytidine within the ACC coldspot and within
the TCG hotspot equally well (Fig. 4, lanes 4 and 5 vs. lanes
10 and 11 all in duplicate), but deamination of deoxycytidine
Figure 3. Recombinant strepAID can deaminate ssDNA.
(a) Schematic of the SNuPE reaction used to detect dC-to-
dU conversion on oligonucleotide substrates. (b) The
SNuPE reaction is specific: given a template with a uridine
at a known position, Bst polymerase will extend a primer
with the addition of the complementary base ( -P32dATP),
but not with any other deoxynucleotide ( -P32dTTP,
 -P32dGTP, or  -P32dCTP). (c) StrepAID-treatment of a
template containing a single dC can lead to its deamination
to dU. This conversion event requires active strepAID
(duplicate lanes 5 and 6), and does not happen when the
template is incubated with BSA (duplicate lanes 1 and 2) or
with a strepAID active site mutant (E58Q/C87A/C90A,
duplicate lanes 3 and 4). In addition, dsDNA is not deami-
nated by strepAID (lanes 7 and 8). Right panel: SNuPE of
U-containing oligos serves as a calibration curve (lane
12   signal from 100% U-containing template, lane 11  
signal from 10% U template and 90% C template, lane
10   signal from 1% U template-99% C template, lane
9   C-template alone).
Figure 4. Recombinant strepAID does not display
hotspot preference. StrepAID deaminates a single C in
the context of a TCG hotspot or an ACC coldspot. In
these reactions, the C-to-U deamination efficiency is
equivalent ( 1% to 5% of templates are deaminated).
The experiments shown are done in duplicate using in-
dependent protein preparations. Left panel: SNuPE of
U-containing oligos as a calibration curve (lane 1  
signal from 10% U-containing template and 90%
C-containing template, lane 2   signal from 1% U
template-99% C template, lane 3   C-template alone).T
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in the context of AGC, GCT, or TCT, was at background
levels (unpublished data). It is theoretically possible that the
sequence context of the trinucleotides is important and that
the “inactive” trinucleotides (like AGC) were not couched
in the optimal context, though the contribution of neigh-
boring bases to the targeting of a particular trinucleotide has
not been studied. We have tested ACC, TCG, and AGC in
several sequence contexts and have found that ACC and
TCG were deaminated whereas AGC was not (unpublished
data). We conclude that although AID prefers to deaminate
deoxycytidines within certain sequences, this selectivity does
not mirror the preference of the hypermutation machinery,
and hence, that hotspot preference may be attributed to a
different factor. This unknown protein may act early in the
reaction, marking specific deoxycytidines for deamination.
Alternatively, hotspot preference may reflect the preference
of the repair machinery for error correction (19).
Taken together, our data suggest that the role of AID in
hypermutation is to bind and deaminate single stranded
DNA. In vivo, single stranded DNA may arise transiently
during transcription, in which case our data would strongly
predict that AID activity must be tightly coupled to the tran-
scriptional apparatus, as previously envisioned (20). Alterna-
tively, more stable single stranded DNA structures might
arise through the formation of stalled transcription forks,
R-loops (as has been described for CSR [21]), or through
the action of a single or double stranded nuclease. If AID
functions as a single stranded DNA deaminase in vivo, it will
be interesting to see what processes generate its target DNA.
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